The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Eltrombopag (Brand name: Promacta)
- Manufactured by
Novartis Pharmaceuticals Corp.
FDA-approved indication: November 2018, eltrombopag (Promacta) was approved in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. In August 2014, it was approved for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
National Library of Medicine Drug Information PortalMedline Plus Health Information